The results showed that the use of high‐dose IL‐1 inhibitor in patients with ARDS because of COVID‐19 is associated with a higher survival rate compared to lower doses (90% vs. 56%, p = .009) and is effective in improving the clinical condition of patients outside the ICU, inflammatory factors, and the need for mechanical ventilation.18 The gene discussed is IL1B; the disease is acute respiratory distress syndrome.